Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil in Raynaud's Phenomenon
NCT02583789Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- May 2016
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of treprostinil in Raynaud's phenomenon (RP), sponsored by Brigham and Women's Hospital. Started May 2016; status: completed.
02
Drugs
treprostinil
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT02583789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583789.